These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38853005)

  • 1. Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.
    Xu Y; Wang Y; Wu R; Zheng C; Zhang L; Xu W; Feng X; Wang H; Cao X; He L; Xue T; Jin M; Xie B; Ling J; Sun L; Su R; Cheng H; Fang Y; Poon MC; Liu W; Zhang L; Xue F; Yang R
    Haemophilia; 2024 Jul; 30(4):959-969. PubMed ID: 38853005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding control improves after switching to emicizumab: Real-world experience of 177 children in the PedNet registry.
    van der Zwet K; de Kovel M; Motwani J; van Geet C; Nolan B; Glosli H; Escuriola Ettingshausen C; Königs C; Kenet G; Fischer K;
    Haemophilia; 2024 May; 30(3):685-692. PubMed ID: 38578720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors.
    Shima M; Nogami K; Nagami S; Yoshida S; Yoneyama K; Ishiguro A; Suzuki T; Taki M
    Haemophilia; 2019 Nov; 25(6):979-987. PubMed ID: 31515851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.
    McCary I; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Ballester L; Raffini L
    Haemophilia; 2020 Jul; 26(4):631-636. PubMed ID: 32311809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.
    Barg AA; Budnik I; Avishai E; Brutman-Barazani T; Bashari D; Misgav M; Lubetsky A; Kuperman AA; Livnat T; Kenet G
    Haemophilia; 2021 May; 27(3):383-391. PubMed ID: 33892524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
    Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world data on the use of emicizumab in patients with haemophilia A with and without inhibitors in Singapore.
    Lee MW; Cheong MA; Ng HJ; Tien SL; Lam JCM
    Ann Acad Med Singap; 2023 Nov; 52(11):580-589. PubMed ID: 38920147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.
    Samelson-Jones BJ; Guelcher C; Kuhn J; Butler R; Massey G; Guerrera MF; Raffini L
    Haemophilia; 2021 Jul; 27(4):591-598. PubMed ID: 34050689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emicizumab in pediatric hemophilia: Bleeding and surgical outcomes from a single-center retrospective study.
    Cohen CT; Diaz R
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29325. PubMed ID: 34490988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
    Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
    Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence.
    Kenet G; Fujii T
    Haemophilia; 2024 Mar; 30(2):267-275. PubMed ID: 38291654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
    Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
    Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
    Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
    Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.